Search results for "Virology"

showing 10 items of 2354 documents

Chronic hepatitis B in Italy: New features of an old disease - Approaching the universal prevalence of hepatitis B e antigen-negative cases and the e…

2008

We evaluated 1336 hepatitis B surface antigen-positive subjects consecutively observed in 79 Italian hospitals over a 6-month period. The proportion of hepatitis B e antigen-negative cases was 86.4%, that of patients coinfected with hepatitis D virus was 9.7%, and the rate of patients coinfected with hepatitis C virus was 16.8%. Multiple logistic regression analysis showed that age >49 years, alcohol abuse, and anti-hepatitis D virus and anti-hepatitis C virus positivity were independent predictors of progression to liver cirrhosis. © 2007 by the Infectious Diseases Society of America. All rights reserved.

Liver CirrhosisAdultMaleMicrobiology (medical)medicine.medical_specialtyCirrhosisAdolescentHepatitis D ChronicHepatitis C virusHepacivirusLiver CirrhosiHepacivirusmedicine.disease_causeGastroenterologyVirusFlaviviridaeHepatitis B ChronicSeroepidemiologic StudiesInternal medicinemedicineHumansHepatitis B e AntigensAgedAged 80 and overCross-Sectional StudieHepacivirubiologybusiness.industrySeroepidemiologic StudieHepatitis Delta ViruHepatitis BMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis DVirologyAlcoholismCross-Sectional StudiesInfectious DiseasesItalyDisease ProgressionFemaleHepatitis B e AntigenHepatitis D virusHepatitis Delta VirusbusinessHuman
researchProduct

Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel

2017

Abstract Hepatitis C virus (HCV) infection remains one of the main causes of chronic liver disease worldwide. The advent of direct-acting antivirals (DAAs) has significantly improved the course of patients with chronic HCV infection (CHC), due to the ability of these drugs to achieve high rates of sustained virological response (SVR). These exceedingly high rates of SVR and the excellent safety data have been confirmed in real life practice. Evolving guidelines have been issued by national and international scientific societies in accordance with the progression of clinical knowledge and the availability of new DAAs. These recommendations, however, may not be applied universally because of …

Liver CirrhosisDirect-acting antiviral agentFibrosiHepacivirusChronic liver diseasemedicine.disease_causeClinical knowledgeVirological response0302 clinical medicine80 and over030212 general & internal medicineChronicAntiviral treatment; Cirrhosis; Direct-acting antiviral agents; Hepatitis C; RAV; Treatment failureAged 80 and overGastroenterologyAntiviral treatment; Cirrhosis; Direct-acting antiviral agents; Hepatitis C; RAV; Treatment failure; Hepatology; GastroenterologyHepatitis CMiddle AgedViral LoadSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CCirrhosisItalyLiverCombination030211 gastroenterology & hepatologyDrug Therapy CombinationHumanAdultmedicine.medical_specialtyConsensusHepatitis C virusLiver CirrhosiConsensuAntiviral AgentsUnmet needs03 medical and health sciencesYoung AdultDrug TherapyInternal medicinemedicineHumansIntensive care medicineAgedAntiviral AgentHepaciviruCirrhosiHepatologybusiness.industryHepatologyHepatitis C Chronicmedicine.diseaseVirologyFibrosisAntiviral treatmentTreatment failurePosition paperAntiviral treatment; Cirrhosis; Direct-acting antiviral agents; Hepatitis C; RAV; Treatment failure; Adult; Aged; Aged 80 and over; Antiviral Agents; Consensus; Drug Therapy Combination; Fibrosis; Hepacivirus; Hepatitis C Chronic; Humans; Italy; Liver; Liver Cirrhosis; Middle Aged; Viral Load; Young AdultDirect-acting antiviral agentsRAVbusiness
researchProduct

Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease

2017

Background & Aims: We investigated the efficacy and safety of simeprevir plus daclatasvir in treatment-naïve patients with chronic, genotype 1b hepatitis C virus infection and advanced liver disease, excluding patients with pre-defined NS5A resistance-associated substitutions. Methods: This phase II, open-label, single-arm, multicentre study included patients aged ≥18 years with advanced fibrosis or compensated cirrhosis (METAVIR F3/4). Patients with NS5A-Y93H or L31M/V resistance-associated substitutions at screening were excluded. Simeprevir (150 mg)+daclatasvir (60 mg) once daily was administered for 12 or 24 weeks; treatment could be extended to 24 weeks prior to or at the Week 12 v…

Liver CirrhosisMale0301 basic medicineSimeprevirPyrrolidinesCirrhosisSustained Virologic ResponseHepacivirusmedicine.disease_causeGastroenterologyLiver disease0302 clinical medicineRecurrencehepatitis C viruMultivariate AnalysiAged 80 and overImidazolesValineMiddle AgedRNA ViralDrug Therapy CombinationFemale030211 gastroenterology & hepatologyHumanmedicine.drugAdultmedicine.medical_specialtyDaclatasvirGenotypeLogistic ModelLiver CirrhosiHepatitis C virussimeprevirAntiviral AgentsViral RelapseYoung Adult03 medical and health sciencesInternal medicinemedicineHumansdaclatasvirAdverse effectImidazoleAgedAntiviral Agentresistance-associated substitutionHepaciviruHepatologybusiness.industryHepatitis C Chronicgenotype 1bmedicine.diseaseVirologyRegimenLogistic Models030104 developmental biologyMultivariate AnalysisCarbamatesbusinessLiver International
researchProduct

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

2007

The effect of achieving a sustained virological response (SVR) following interferon-α (IFNα) treatment on the clinical outcomes of patients with HCV-related cirrhosis is unknown. In an attempt to assess the risk of liver-related complications, HCC and liver-related mortality in patients with cirrhosis according to the response to IFNα treatment, a retrospective database was developed including all consecutive patients with HCV-related, histologically proven cirrhosis treated with IFNα monotherapy between January 1992 and December 1997. SVR was an undetectable serum HCV-RNA by PCR 24 weeks after IFNα discontinuation. HCC was assessed by ultrasound every 6 months. Independent predictors of al…

Liver CirrhosisMaleANTIVIRAL TREATMENTMultivariate analysisCirrhosisHepacivirusdrug therapy/mortality/virologyGastroenterologyCohort StudiesINTERFERON; HEPATITIS C; CIRRHOSIS; CHRONIC HEPATITIS C; ANTIVIRAL TREATMENT; SUSTAINED VIROLOGICAL RESPONSE; Liver cirrhosis.MedicinegeneticsLongitudinal StudiesViralCIRRHOSISHazard ratiovirus diseasesHepatitis CAdult Antiviral Agents; therapeutic use Cohort Studies Female Hepacivirus; genetics Hepatitis C; blood/complications/drug therapy/mortality Humans Interferon-alpha; therapeutic use Liver Cirrhosis; drug therapy/mortality/virology Longitudinal Studies Male Middle Aged Multivariate Analysis RNA; Viral; blood Retrospective Studies Survival Analysis Treatment OutcomeMiddle AgedLiver cirrhosis.Treatment OutcomeSUSTAINED VIROLOGICAL RESPONSEHEPATITIS CLiver Cirrhosis/drug therapy Liver Cirrhosis/virologyRNA ViralFemaleAdultINTERFERONmedicine.medical_specialtyCHRONIC HEPATITIS CAntiviral AgentsbloodInternal medicineHumansRetrospective StudiesSustained virological response interferon-alpha HCV-related cirrhosis:Hepatologybusiness.industryProportional hazards modelInterferon-alphaRetrospective cohort studyblood/complications/drug therapy/mortalityHepatologymedicine.diseaseSurvival Analysisdigestive system diseasesDiscontinuationSurgerytherapeutic useMultivariate AnalysisRNAbusiness
researchProduct

Genetic similarity of hepatitis C virus and fibrosis progression in chronic and recurrent infection after liver transplantation

2006

SUMMARY. The effect of hepatitis C virus (HCV) genetic heterogeneity on clinical features of post-transplantation hepatitis C is controversial. Different regions of the HCV genome have been associated with apoptosis, fibrosis, and other pathways leading to liver damage in chronic HCV infection. Besides, differences in immunodominant regions, such as NS3, may influence HCV-specific immune responses and disease outcome. In the liver transplant setting, a recent study has reported a positive association between HCV-1b Core region genetic relatedness 5-year post-transplantation and histological severity of recurrent hepatitis C. We have compared nucleotide sequences of HCV Core, NS3 and NS5b re…

Liver CirrhosisMaleCirrhosisBiopsyHepatitis C virusmedicine.medical_treatmentGenome ViralHepacivirusViral Nonstructural ProteinsLiver transplantationBiologymedicine.disease_causeVirusCohort StudiesSpecies SpecificityRecurrenceFibrosisVirologymedicineHumansHepatologySequence Analysis RNAGenetic heterogeneityViral Core Proteinsvirus diseasesHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseasedigestive system diseasesLiver TransplantationChronic infectionInfectious DiseasesLiverSpainImmunologyDisease ProgressionFemaleJournal of Viral Hepatitis
researchProduct

Efficacy and safety of direct-acting antiviral therapy in previous hard-to-treat patients with recurrent hepatitis C virus infection after liver tran…

2017

Sebastian Bernuth,1 Daniel Grimm,1 Johanna Vollmar,1 Felix Darstein,1 Jens Mittler,2 Michael Heise,2 Maria Hoppe-Lotichius,2 Peter R Galle,1 Hauke Lang,2 Tim Zimmermann1 1First Department of Internal Medicine, Transplant Hepatology, 2General-, Abdominal- and Transplant- Surgery, University Medical Center, Johannes Gutenberg University, Mainz, Germany Background: Recurrent hepatitis C virus (HCV) infection after liver transplantation (LT) has been a frequent and relevant problem in the past two decades. This analysis evaluated the efficacy and safety of new interferon (IFN)-free direct-acting antiviral (DAA) therapies in a large real-world cohort of HCV patients after LT.Methods: We retrospe…

Liver CirrhosisMaleHepacivirusmedicine.medical_treatmentPharmaceutical ScienceHepacivirusLiver transplantationGastroenterologyCohort Studieschemistry.chemical_compound0302 clinical medicineRecurrenceDrug DiscoveryMedicine030212 general & internal medicineOriginal Researchbiologyliver transplantationvirus diseasesMiddle AgedTreatment OutcomeCohortHCV030211 gastroenterology & hepatologyDrug Therapy CombinationFemalesustained virological responseCohort studymedicine.medical_specialtySVRAntiviral Agentsreinfection03 medical and health sciencesInternal medicineHumansSurvival analysisAgedRetrospective StudiesDAAPharmacologyDrug Design Development and Therapybusiness.industryRibavirinRetrospective cohort studyHepatitis C Chronicbiology.organism_classificationVirologySurvival Analysisdigestive system diseasesDiscontinuationchemistrybusinessDrug design, development and therapy
researchProduct

HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome.

2015

Aim: To evaluate similarities and differences in HCV-1 subtypes 1a and 1b in the presenting clinical features and the response to peg-interferon and ribavirin (Peg/RIBA).Patients and methods: A total of 1,233 naïve patients with HCV genotype-1 infection, 159 (13 %) with subtype 1a and 1,074 (87 %) with subtype 1b were treated with Peg-IFN/RIBA at 12 Italian centers. Covariates included in the logistic model were age, gender, BMI, serum alanine aminotransferase, serum gamma-glutamiltranspeptidase (γGT), platelets counts, liver fibrosis, the occurrence of type 2 diabetes, baseline viremia, and IL28B genotype.Results: At multivariate analysis, baseline characteristics differentiating patients …

Liver CirrhosisMaleMultivariate analysisclinical featuresChronic HCV liver diseaseType 2 diabetesSex FactorHepacivirusGastroenterologyPolyethylene GlycolPolyethylene Glycolstherapeutic outcomechemistry.chemical_compoundGenotypeAge FactorSettore MED/12 - GastroenterologiaSustained virologic responseAge Factorsvirus diseasesHCV genotype 1 subtypes (1a and 1b)Hepatitis CRecombinant ProteinMiddle AgedRecombinant ProteinsTreatment OutcomeInterferonRNA ViralFemaleHCV subtypeHumanAdultmedicine.medical_specialtyGenotypeLiver CirrhosiAlpha interferonmacromolecular substancesInterferon alpha-2Antiviral AgentsSex FactorsDiabetes mellitusInternal medicineRibavirinmedicineHumansPeg-interferon and ribavirinAntiviral AgentHepaciviruHepatologybusiness.industryRibavirinInterleukinstechnology industry and agricultureInterferon-alphaHepatologyInterleukinHepatitis C Chronicmedicine.diseaseVirologydigestive system diseaseschemistryDiabetes Mellitus Type 2HCV genotypeHCV genotype 1 subtypes (1a and 1b); clinical features; therapeutic outcomeInterferonshepatitis Cbusiness
researchProduct

Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis

2008

BACKGROUND: While the likelihood of developing hepatocellular carcinoma (HCC) in patients coinfected with both HBV and HCV is increased, the role of previous exposure to HBV as a risk factor associated with tumor occurrence in subjects with HCV-related cirrhosis has not been fully investigated. AIM: To assess whether serum anti-HBc positivity, as a marker of previous HBV exposure, is associated with HCC development in HCV-related positive, hepatitis B surface antigen (HBsAg) negative patients with cirrhosis treated with alfa-interferon (IFN) monotherapy. PATIENTS AND: A database including 883 consecutive patients (557 men, mean age 54.7 yr) with histologically METHODS: proven cirrhosis trea…

Liver CirrhosisMalePathologyCirrhosisAdult Antibodies; Viral; blood Carcinoma; Hepatocellular; blood/pathology/virology Cohort Studies Female Hepatitis B Core Antigens; immunology Hepatitis B virus; immunology Hepatitis C; blood/complications/pathology Humans Liver Cirrhosis; blood/etiology/pathology Liver Neoplasms; blood/pathology/virology Male Middle Aged Retrospective Studies Risk FactorsAntibodies ViralGastroenterologyanti HBcCohort StudiesimmunologyRisk FactorsHBVViralHCCCIRRHOSISLiver NeoplasmsGastroenterologyvirus diseasesHBV HCV COINFECTIONMiddle AgedHepatitis B Core AntigensHepatitis CAdult; Antibodies Viral; Carcinoma Hepatocellular; Cohort Studies; Female; Hepatitis B Core Antigens; Hepatitis B virus; Hepatitis C; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Retrospective Studies; Risk Factors; GastroenterologyHepatocellular carcinomaHCVFemaleAdultmedicine.medical_specialtyHepatitis B virusCarcinoma Hepatocellularblood/pathology/virologyAntibodiesbloodblood/complications/pathologyInternal medicinemedicineHumansIn patientHEPATOCELLULAR CARCINOMAHEPATOCELLULAR CARCINOMA; HCV; HBV; CIRRHOSIS; HBV HCV COINFECTIONRetrospective StudiesHepatologybusiness.industryCarcinomaCancerHepatocellularmedicine.diseasedigestive system diseasesblood/etiology/pathologybusiness
researchProduct

Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta.

2001

Although many patients with chronic viral hepatitis C infection suffer from progressive liver disease, the rate of fibrosis progression is highly variable and some patients do not show any measurable progression. However, our ability to predict which patients progress is very limited. Since transforming growth factor-beta (TGF-beta) is a key mediator of liver fibrogenesis, we assessed the predictive role of TGF-beta for fibrogenesis in chronic hepatitis C. We studied 39 patients with chronic hepatitis C in whom two liver biopsies were taken at least 12 months apart, and who did not receive therapy during this period. TGF-beta was measured by bioassay and by ELISA in serum samples taken at t…

Liver CirrhosisMalePathologymedicine.medical_specialtyCirrhosisAntiviral AgentsSeverity of Illness IndexFibrosisPredictive Value of TestsTransforming Growth Factor betaVirologyBiopsymedicineHumansHepatologymedicine.diagnostic_testbusiness.industryAlanine TransaminaseHepatitis CHepatitis C ChronicMiddle AgedViral Loadmedicine.diseaseInfectious DiseasesLiver biopsyPredictive value of testsChronic DiseaseDisease ProgressionFemalebusinessViral loadProgressive diseaseBiomarkersProcollagenJournal of viral hepatitis
researchProduct

Characteristics of HCV positive subjects referring to hospitals in Italy: a multicentre prevalence study on 6,999 cases.

2006

In 2001, 6,999 anti-HCV positive subjects referred to 79 Italian hospital in a 6 months enrollment period were evaluated. Of them, 5,632 (80.5%) tested anti-HCV positive alone, 1,163 (16.6%) reported also an excessive alcohol intake, and 204 (2.9%) were also HBsAg positive. Normal biochemistry was observed in 7.8% of cases, chronic hepatitis in 67.9% of cases, liver cirrhosis in 18.9% of cases, and hepatocellular carcinoma in 3.6% cases. HCV positive subjects with excessive alcohol intake were statistically significantly younger, of male sex, and having more severe liver disease than those without excessive alcohol intake. Adjusting for the confounding effect of age and sex by multiple logi…

Liver CirrhosisMalemedicine.medical_specialtyHBsAgCirrhosisCarcinoma HepatocellularAlcohol DrinkingHepacivirusHepacivirusChronic liver diseaseHCV PositiveLiver diseaseVirologyInternal medicinePrevalenceMedicineHumansHepatologybiologybusiness.industryIncidence (epidemiology)Incidencechronic liver diseaseHepatitis C ChronicMiddle Agedbiology.organism_classificationmedicine.diseaseSurgeryHCV infectionInfectious DiseasesItalyHepatocellular carcinomaRegression AnalysisFemalebusinessJournal of viral hepatitis
researchProduct